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Chapter I 
 
Introduction 
 
  
“Tell me what you know about BioVU.”  
 
Response 1: “Just heard of it, but don’t know what it is.”  
 
Response 2: “On a voluntary basis blood is drawn and the DNA is put in a 
database and stripped of identifying information for research purposes.”  
 
Response 3:“That’s how Vanderbilt is trying to figure out DNA to help find 
treatments for specific individual people.”   
 
  
The preceding quotes reflect three different responses from patients 
concerning Vanderbilt’s de-identified, DNA biobank BioVU. The variations 
presented here are prime examples of patients’ confusion regarding Vanderbilt’s 
biobanking practices. The exit-interview surveys that were conducted for this 
project originated from a series of questions that I had relating to Vanderbilt’s 
efforts to ethically implement the biobank and how that implementation relates to 
Vanderbilt Medical Center’s research practices pertaining to other research using 
leftover biospecimens collected from patients. At Vanderbilt, and other academic 
research hospitals, it is common practice to use any biospecimens for medical 
research. Upon their first encounter with Vanderbilt’s registration system and 
annually thereafter, in order to receive treatment from Vanderbilt patients must 
sign the general Consent to Treat form that includes acknowledging that 
Vanderbilt may use any and all biospecimens remaining after clinical diagnosis or 
treatment for research. Rather than apply the same standards of regular tissue 
and other biospecimen collection, the standards for BioVU are different because 
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BioVU specifically concerns the collection of DNA. In addition to having patients 
sign the Consent to Treat form, Vanderbilt also presents patients with the option 
to opt-out of participation in BioVU. For the general consent to treat, the 
possibility to opt-out of having other biospecimens used for research is not made 
available. The inconsistency of these practices is troublesome to many who are 
aware of the discrepancy, including, but not limited to, Vanderbilt’s Ethics 
Committee, patient educations, and others within the Vanderbilt community that 
had this issue brought to their attention. As a member of the Vanderbilt 
community who is concerned about this issue, I wanted to know whether patients 
are also aware that even if they opt-out of participation in BioVU that not only 
could their leftover blood and DNA be used for other types of research, but any 
and all other biospecimens collected from routine tests and procedures could be 
as well.  
In 2013, Vanderbilt pediatrician Kyle Brothers and his colleagues (2013) 
published a study measuring patients’ awareness of BioVU. Between 2009 and 
2012, Brothers and his colleagues conducted three sets of patient exit-interviews. 
Beginning in 2009, they interviewed adult patients who were having their blood 
drawn at two of the busiest phlebotomy labs in Vanderbilt University Medical 
Center. These 68 adult interviews were later compared with a second cohort of 
77 exit-interviews collected in 2011 in the same locations to compare whether 
awareness was affected by new institutional campaigns that sought to increase 
the visibility of BioVU. Between these two time periods, exit-interviews were also 
conducted to include awareness on part of parents of pediatric patients who  
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were having blood drawn at Monroe Carrell Jr. Children’s Hospital at Vanderbilt. 
However, the focus of this study is on the adult cohorts since this project is 
revisiting awareness of adult primary care patients at Vanderbilt. The primary 
outcomes measured were: 
(1) Awareness of the Vanderbilt DNA databank 
(2) Awareness that leftover blood could be used for research 
(3) Support for the biorepository (p. 351) 
 
Brothers et al found that while 92.5% of all adults surveyed reflected support for 
DNA databank after being offered a brief description of the project, awareness 
was still low.  Only 48.1% and 32.5% of people in the Adult 1 and Adult 2 cohorts 
had heard of BioVU previously; 34.3% and 50% were aware that leftover 
specimens could be used from research; 2.6% and 2.5% could recall their choice 
of opting-out of participating in BioVU. The authors concluded that “the opt-out 
procedures utilized by BioVU [were] not yet optimal” and hypothesized that by 
moving to a kiosk-based electronic consent process from the paper-based 
consent process would improve patients’ awareness of BioVU. (Brothers et al, 
2013). 
The current research project is intended to be an extension of the previous 
study, and assesses whether kiosk-based consent processes implemented in 
Vanderbilt clinics in January of 2013 have increased awareness of BioVU. In 
addition to re-measuring awareness, there was interest in measuring patients’ 
awareness of Vanderbilt’s’ research practices regarding the use of other 
biospecimens not pertaining to BioVU (Brothers et al, 2013). These ideas were 
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proposed to BioVU planners to start a conversation regarding what the next 
survey might look like and how the research could be of use to Vanderbilt and 
BioVU. BioVU planners were concerned that the new questions could confuse 
and/or anger patients The looming confusion would potentially originate from my 
asking questions related to BioVU in combination with questions related to tissue 
research in the same survey, thus causing patients to think that BioVU involved 
more than just banking DNA samples collected from leftover blood drawn for 
routine lab testing. The anger, on the other hand, was expected to result from 
patients’ frustration with their biological materials being used for research as well 
as concern, if my questions were in fact misconstrued, that Vanderbilt had not 
been transparent in their consent practices. It was made clear that if questions 
regarding the use of other biological materials unrelated to BioVU were included 
in the study, collaboration with BioVU planners for this project would be more 
difficult since the questions were seen to pose a risk to the trust BioVU planners 
had built within the Vanderbilt and Nashville community.   
The process of informing patients of BioVU will be explained in further 
detail, but until then attention should be focused on how and why. It seems that 
BioVU planners’ interests for BioVU came before patient interests. BioVU 
planners have drawn significant attention their initiatives to raise community 
awareness and support for BioVU specifically. The goals of these efforts have 
been to increase awareness and patient access to information. Disappointingly, 
the evidence of increasing rates of awareness is unconvincing, especially since 
patients are not presented with adequate information about what BioVU is prior 
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to the time of deciding whether they agree to participate. This skepticism was not 
unfounded since previous informal interactions with friends, colleagues, and 
other acquaintances with varying levels of involvement with the Vanderbilt and 
Nashville communities concerning the ethics of biobanking practices almost 
always resulted in the question: “Biobanking? What’s that?” Because these 
questions were coming from generally well-educated, involved members of 
Vanderbilt University, Vanderbilt University Medical Center, and even from 
medical professionals at other surrounding hospitals, it was suspected that 
surveying the general patient population would confirm this skepticism.   
For this project, 61 adult patients were surveyed to answer the following 
questions:  
(1) Are Vanderbilt patients aware of BioVU?  
(2) Do patients actually know what BioVU is?  
(3) Do patients realize their participation in BioVU?  
(4) Do patients want more information?  
(5) If the information is made available to them, will they access it? 
The answers to these questions address the concerns that BioVU planners have 
expressed regarding the problem of confusion and help to illustrate the source of 
that confusion. BioVU planners have worried that giving patients too much 
information regarding BioVU will lead to confusion. It was hypothesized first that 
the confusion that BioVU planners cited as a reason to limit information is caused 
not by patients having too much information, but instead from having too little. In 
such case, is was hypothesized second that the confusion is a direct result of 
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BioVU planners decisions on which information is or is not necessary for patients 
to have regarding their participation in the project.  
To address this hypothesis, this project seeks to meet three objectives: to 
provide a general overview of what biobanking is, address the implementation of 
Vanderbilt’s biobanking practices, and measure current rates of patient 
awareness regarding BioVU. Pursuing these objectives will allow effective 
analysis of the current state of Vanderbilt’s biobank through an ethically critical 
lens, followed by recommendations for how BioVU can improve patients’ 
awareness and understanding of the project. In the context of BioVU in particular, 
it is appropriate to critically analyze some presumptions regarding BioVU’s 
success, efficacy, and ethical practice. BioVU is a successful and nationally 
recognized DNA biobank, and it fulfills more ethical standards than is required by 
federal legislation. However, even in this context, the practice of informing 
patients of the project should not be revisited and cannot be improved.  
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Chapter II  
 
 
Background 
 
  
Biobanking 
 
Shaw, Elger & Colledge (2014) conducted a systemic review of varying 
definitions of biobanks. After conducting interviews with 36 biobanking 
stakeholders, including project managers, pathologists, researchers, clinicians, 
lawyers, and ethicists, all with experience working with international biobanking, 
the authors found that most definitions agree that “biobanks are repositories of 
biological samples with accompanying linked data” (p. 226). The definition 
provided by the Swiss Academy of Medical Sciences (SAMS) is even more 
detailed. SAMS defines biobanks as “systematic collections of samples of human 
body substances (e.g. organs, tissue, blood, cells, etc.) and DNA as carrier of 
genetic information. Data that contain information on the donor (demographic 
data, type of disease, etc.), but also genetic data, are stored, either together with 
the samples or separately” (Shaw, Elger & Colledge, 2014, p. 226).   
Multiple objectives underlie the goals of developing large-scale biobanks. 
Biobanks are developed for research purposes so that researchers have 
numerous samples of tissue, organs, blood, cells, or DNA at their disposal. With 
the samples being connected in some way to data from the participant’s medical 
record, the intent is for researchers to be able to identify samples containing 
specific genomic characteristics that would be relevant to their research projects. 
Riegman and colleagues (2008) explain that enabling access to samples is the 
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key motivation in developing biobanks. Having high quality samples is the key 
motivating factor for inspiring large-scale multi-center research projects between 
varying research institutions. There were at least 179 biobanks in the United 
States as of 2011 according to Simon and colleagues (2011), and many hope to 
increase collaboration between researchers to further advance research efforts. 
 
Ethical Concerns  
Since biobanks are such a valuable resource for the advancement of 
research, scholars such as Widdows & Cordell (2011) state that they “require a 
rethinking of our ethical assumption and frameworks which have applied 
generally to other issues in ethics” because they are a new territory worthy of 
consideration (p. 207). Ethical concerns for biobanks have traditionally been 
related to privacy and identification of patients related to their biospecimen 
samples, informed consent, incidental findings in research, accountability to 
patients from whom the materials were derived and whether individuals whose 
materials have been used to develop effective treatments for their medical 
conditions and whether they will have access to new treatments. Biobanking is 
unique because it does not fit neatly into a singular focus area of medical ethics. 
It breaches barriers as the materials to build biobanks come from patients 
receiving clinical care, but the samples themselves are not classified as research 
subjects as traditionally defined in the realm of human subjects research. 
Because of this difference, the traditional standards applied to human subjects 
research do not apply with the same weight, especially in terms of obtaining 
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informed consent. This difference in common standards of informed consent in 
human subjects research is the key ethical problem that will be explored 
throughout the rest of this document.  
 
Informed Consent  
 The evolution of informed consent practices pertaining to human subjects 
research formally after the Nuremburg Code established the first set of standard 
protections to be applied to research involving human subjects. The Nuremburg 
Code specified, “the voluntary consent of the human subject is absolutely 
essential” (Washington DC: US Government Printing Office, 1949).  To improve 
and reinforce these expectations for obtaining consent from participants, the first 
version of the Declaration of Helsinki was drafted in 1964, expanding on the 
Nuremburg Code specifically to address those who may be considered 
vulnerable or have difficulties understanding the goals of the research they may 
contribute to. Since that time, As pitfalls were identified and caused problems for 
increasingly vulnerable persons, the Declaration has been revised and expanded.  
 In 1964, the Declaration specified that consent should not only be 
voluntary but also informed, and that research subjects should not be coerced by 
physicians who would benefit from the subject’s participation. It also allowed for 
consent to be obtained from legal guardians in cases of incompetent persons. At 
any time, the subject could withdrawal from the study. The revision that took 
place in 1989 further specified that informed consent could not be inferred from a 
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personal interaction between patient/subject and physician, but must be obtained 
in writing and/or formally documented.  
 The 2000-2004 revisions further began to emphasize respect and 
recognition for those who could not consent for themselves, such as minors and 
the physically and/or mentally incompetent. In such cases, consent should be 
obtained from legally authorized representatives. These vulnerable populations 
could only be included in research if and only if “the research is necessary to 
promote the health of the population represented and this research cannot 
instead be performed on legally competent persons” (World Medical Association, 
2008). The 2008 revision included that consent must be normally obtained, but 
may sometime be omitted in the interest of protecting the validity of a study 
where informed consent would compromise the outcome such as in cases of 
using identifiable human materials. Instead, researchers must go before a 
committee to have the requirement for informed consent suspended.  
  In the United States, protection for human subjects research is heavily 
influenced by the Belmont Report, which takes a principle-based approach 
advocating for (1) Respect for Persons, (2) Beneficence, and (3) Justice. 
Informed consent is addressed under the first principle of Respect for Persons, 
which equates to allowing participants to exercise their self-determination in 
choosing to participate in research studies. This requires researchers to provide 
appropriate information to the study’s potential participants, who may or may not 
choose to enroll in based on the information regarding risks and benefits 
provided to them before giving their consent to enroll. Human subjects research 
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in the United States is also guided by the “Common Rule” or HHS Regulations 45 
CFR § 46 that outlines basic requirements and provisions for Institutional Review 
Boards, informed consent practices, and compliance. For informed consent, the 
“Common Rule” states at 46.116(a):  
 
An investigator shall seek such consent only under circumstances that 
provide the prospective subject or the representative sufficient opportunity 
to consider whether or not to participate and that minimize the possibility 
of coercion or undue influence. The information that is given to the subject 
or the representative shall be in language understandable to the subject or 
the representative. No informed consent, whether oral or written, may 
include any exculpatory language through which the subject or the 
representative is made to waive or appear to waive any of the subject’s 
legal rights, or releases or appears to release the investigator, the sponsor, 
the institution or its agents from liability for negligence (Protection of 
Human Subjects, 2009).  
 
Each subject should be provided with a statement that explicitly states the study 
is for research, the purposes of the research, duration of participation, description 
of potential risks and benefits, how records will be maintained, who to contact 
with questions and concerns, and the option of withdrawal or refusal at any time 
with no penalty to the participant.  
 
Biobanking Meets Informed Consent  
Biobanking practices regarding consent, however, are perplexing to 
researchers, ethicists, and regulatory officials alike since the concept is still 
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relatively new. Because biobanks are resources that collect samples to be used 
for future research, it is difficult to provide all relevant information regarding the 
types of studies and how exactly the collected materials may be used, if they are 
to be used at all. As noted by Shickle (2006) patients that agree to be 
participants are consenting to multiple things, such as allowing the collection of 
personal DNA and data, the collection of DNA and data to be used in ways other 
than testing, and also for research to be performed on the collected data and 
DNA. This can often prove to be a difficult feat in developing a more than 
adequate consent procedure because there is no way to describe detailed 
information regarding the research to be conducted on the collected materials at 
the time of recruitment. Despite this challenge, efforts to create successful 
biobanks have not been significantly affected.  
To help create some standardization in approaching consent models for 
biobanks, biological specimens that are collected without having any private, 
identifying information attached are exempt from the normal provisions of human 
subjects research. This is possible because the Office of Human Research 
Protection has specified that these remains do not meet the definition of a 
“human subject” as defined at 45 CFR § 46.102(d):  
 
Human subject means a living individual about whom an investigator 
(whether professional or student) conducting research obtains  
(1) data through intervention or interaction with the individual, 
or  
(2) identifiable private information (OHRP, 2008) 
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Thus, it is permissible for institutions and researchers to not develop an informed 
consent protocol for their biobanks. However, a consent protocol is still often 
used due to the perceived need to “satisfy public and other stakeholder 
expectations for being informed and given the opportunity to refrain from 
research participation” (Simon et al, 2011).  
Consent is gathered in one of three ways: (1) general or blanket consent, 
(2) opt-in consent, or, most controversially, (3) opt-out consent. General or 
blanket consists of gathering consent from everyone who may come through a 
particular health care system, including from individuals who may never become 
participants. This approach is seen as problematic because it is difficult to  inform 
participants adequately of the true nature of their participation because it is 
possible that they will never be participants and because of the chance for 
confusion or misunderstanding that the consent is  for future purposes as well as 
current research efforts (Simon et al, 2011). Opt-in consent is a method through 
which systems give  everyone as much information as possible for the potential 
participants to be able to make an informed decision. The problems associated 
with opt-in models are comparable to those associated with general or blanket 
consent.  
The opt-out model of consent is arguably not a method of obtaining 
consent, but more so of gaining assent. Upon introduction to an opt-out biobank, 
patients are given the opportunity to decline participation. This is the trickiest of 
approaches to gaining consent for a number of reasons. First, it assumes that the 
patients realize they have a choice and can effectively say no. In turn, it also 
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assumes that the person filling out the paper work is competent to opt-out if they 
so choose. Most importantly, the ability for the patient to make an informed 
decision depends entirely and explicitly on the public availability of information, 
especially at the time of decision (Shickle, 2006). The availability of that 
information is entirely the responsibility of the sponsoring institution to decide 
what is and is not necessary or appropriate for patients to have at, before, or 
after that time.  
 
BioVU   
Vanderbilt’s de-identified DNA biobank BioVU utilizes an opt-out model of 
participation. It has had a remarkable amount of success and is one of the 
largest DNA biobanks in the country. BioVU planning has been an ongoing effort 
since 2004, and as of mid-2012, BioVU had over 150,000 samples, with 600-800 
new samples accrued daily (Vanderbilt University, 2014). In the literature, BioVU 
is most well known for its opt-out consent model and is often referred to as a 
case study in the opt-out approach. In 2011, BioVU planners explained the 
success of their approaches while boasting their commitment to ethical 
biobanking practices. Vanderbilt recognizes that the Office of Human Research 
Protections has granted exemption status to remaining biological materials such 
as tissues, organs, blood, etc. under 45 CFR § 46; however BioVU planners 
have attempted to apply the standards of the Belmont Report to BioVU to ensure 
ethical research practices in recruiting participants for BioVU.  
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 To obtain samples for BioVU, DNA is extracted from leftover blood that 
would otherwise be discarded. In this method, , no interaction is needed with the 
patient as a research subject. While these samples undergo a de-identification 
process, each sample is linked to data collected from the patient’s electronic 
medical record. The de-identified data collected from the EMR is referred to as 
the Synthetic Derivative (SD).  
 In applying the standards of the Belmont Report to BioVU, program 
planners received a great amount of multidisciplinary input from multiple 
committees and boards including,: the Medical Center Ethics Committee and  the 
Medical Records Committee, as well as creating an institutional operations 
oversight committee established specifically for BioVU, and a Community 
Advisory Board also established specifically for the project.  BioVU also 
underwent initial review and receives on going oversight of the resource and its 
use by the IRB (Pulley et al, 2010, p. 43). 
Each of these groups contributed to the analysis and implementation of 
BioVU in compliance with the principles as outlined in the Belmont Report, first 
beginning with how patients who identify as potential participants would be 
notified of the program and asked whether they are willing to participate. In order 
to preserve the boundary between clinical care and research participation, 
Vanderbilt decided to implement a separate section within the normal patient 
registration procedures in order to gain consent for participation. To do this, the 
Consent to Treatment/Agreement to Pay form was expanded to include 
explanations that research on tissues and other biospecimens that are collected 
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from medical procedures and tests may be used in research. It also explicitly 
notifies patients of the DNA Databank. At the time of this writing, the form stated:  
I understand and agree that any specimens or tissues normally removed 
from my body by VUMC in the course of surgery, or medical treatment that 
would otherwise be disposed of may be retained, used for educational 
purposes or research, including research on the genetic material (DNA) or 
other information contained in those tissues or specimens (Pulley et al, 
2010, p. 43).   
Additionally, the section referring to BioVU participation offers an option to opt-
out in the language as follows:   
 I also understand that if I do not want DNA research to be done using my 
 leftover blood, I need to check the box shown below (Pulley et al, 2010, p.  
43). 
A check box is shown followed by text instructing Vanderbilt not to use leftover 
blood for the DNA databank. It was argued that the text served to “distinguish 
health care from research related to practices and functions that may involve 
data or tissues” and to also preserve the boundary between practice and 
research. While it is understood from a practical standpoint by BioVU planners 
and the supporting oversight that “the Consent to Treatment form is not always 
read in its entirety by patients, and sometimes not read at all”, the goal was still 
to distinguish BioVU from other research pertaining to the use of leftover 
biospecimens collected during medical procedures (Pulley et al, 2010, p. 43). 
BioVU planners argue that they have met the requirement of Respect for 
Persons by making this choice available. 
 BioVU planners met requirements for the principle of Beneficence based 
on the fact that the collection of samples has a decreased risk of harm to 
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individuals with a maximized benefit to the broader society. If we look at BioVU 
from a proportionality perspective, that is if we weigh the risks and benefits 
against each other, the perceived risks to participants are much less than the 
foreseen perceived benefits in research. For instance, because privacy is a 
common ethical concern in the history of the development of biobanking 
practices, Vanderbilt has sought to eliminate that concern via the Synthetic 
Derivative (SD) that completely de-identifies the samples before they are stored 
in BioVU. This is done through creating a second database structure that creates 
a de-identified copy of data from Vanderbilt’s in- and out-patient electronic 
medical record system. If researchers wish to extract certain samples based on 
particular data fields, they can enter them into the SD database and locate 
samples that they need based on that approach (Pulley et al, 2010). Thus, the 
threat of the common ethical concerns are avoided, therefore giving more weight 
to the benefits that can come from having a large-scale biobank as a resource for 
research.  
 In terms of Justice, BioVU is unbiased and nondiscriminatory in terms of 
sample collection. Any and all patients that are 18 years or older who experience 
a laboratory blood-draw and who have also signed a consent to treatment form 
without indicating their wish to opt-out are potential inclusions. Since there 
cannot be any exclusions based on social or demographic data, Justice related 
concerns are non-issues since “the diseases are amenable to research in direct 
proportion to the proportion of individuals who are receiving health care for those 
disease and conditions” (Pulley et al, 2010, p. 46).  
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Improvement  
 Pulley, Clayton, Bernard, Roden & Masys’ analysis of BioVU intends to 
inform other institutions about the initiation of biobanks and the procedures that 
can be employed in order to protect the rights and welfare of the participating 
patient population while also protecting and preserving the potential success of 
such a valuable resource for the progress of genomic research. While BioVU 
planners have made efforts to inform patients of the practice and make them 
more aware of their involvement, they have also limited the information that 
patients receive about the biobank before deciding whether to participate. BioVU 
planners unanimously agreed that patients have a right to be informed of the 
project, but the degree to which patients are informed is not clear. Rid, Emanuel 
& Wendler (2010) express their concerns that this intuition alone raises several 
concerns: 
Clinical research is justified only when participants are protected from 
excessive risks. Yet it is often unclear whether the risks of research 
interventions are acceptable or excessive. Because no systematic 
framework exists for assessing research risks, investigators, funders, and 
institutional review boards (IRBs) currently rely on their intuitive judgment 
to make these determinations (p. 1472).  
 
To address the problems associated with the use of intuition alone in evaluating 
the risks of clinical research, the authors proposed a 4-step method identified as 
the systematic evaluation of research risks (SERR) involving:  
(1) identify[ing] the potential harms posed by the proposed research 
intervention  
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(2) categoriz[ing] the magnitude of the potential harms into 1 of 7 harm 
levels on a harm scale  
(3) quantify[ing] or estimate[ing] the likelihood of each potential harm 
(4) compar[ing] the likelihood of each potential harm from the research 
intervention with the likelihood of harms of the same magnitude 
occurring as a result of an appropriate comparator activity (p. 1472). 
 
This proposal was created in light of addressing intuition-based assessments of 
the risks posed by clinical research so that the influence of cognitive biases are 
minimized, thus furthering protection for potential research participants (Rid, 
Emmanuel & Wendler, 2010). While this method is not directly applicable to the 
practice of biobanking since the harm in collecting biospecimens from patients is 
so minimal, it does allow for the recognition of the need to revisit existing 
practices and procedures because the bias of those involved can inhibit abilities 
to recognize what is and is not harmful or is and is not appropriate.  
Using quantitative and qualitative data collected from exit-interviews with 
Vanderbilt patients, I will show what patients know and what they expressed 
interest in knowing about BioVU. In doing so, I will also critique the power 
dynamic between BioVU planners and potential BioVU participants in that BioVU 
planners choose what and how much information is made available to 
participants. The main contributing factor to the confusion surrounding BioVU has 
been from how BioVU planners have decided to present the limited amount of 
information that was made available previously. Limiting the information that is 
made available to patients has been intended to address or avoid the problem of 
confusion, but it may actually have only made the problem worse. BioVU 
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planners believe that the current information available to patients helps them 
make decisions without burdening them with unnecessary details that may or 
may not be of direct interest to patients. It is here that it becomes clear that 
BioVU planners have exercised their own intuitions in order to make these 
determinations. With this bias becoming apparent, it is fair to revisit current 
BioVU structure and how patients are informed of the project before they become 
participants.  
The goal of this project is not to rehash any of these debates about bias 
and disclosure, as most have been settled throughout the medical and bioethical 
communities that have been involved in the discussions. Instead, my goal is to 
offer a critical perspective of the process through which ethicists and researchers 
have come to justify biobanking “best practices” in informing patients and 
ensuring patient awareness of their involvement with biobanks with specific 
reference being made to Vanderbilt’s DNA databank, BioVU. Providing this 
critique will be useful not only for ongoing biobanking development efforts, but 
also for continuing ethical analyses that will improve the ways in which biobanks 
are implemented so that they can be utilized to provide better support for 
researchers.  
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Chapter III 
 
Patient Awareness of BioVU  
 
Methods 
 In April and May of 2014, I conducted exit interviews with adult patients 
outside the waiting areas for the Adult Primary Care Center and associated 
phlebotomy area who were either leaving from having their blood drawn or 
leaving from their appointments with their primary care providers. The survey 
design for this study was influenced by a previous survey instrument that was 
used by Brothers and his colleagues (2013) to measure patients’ awareness of 
BioVU, awareness that leftover blood could be used for research, and support for 
the biorepository. Using similar methods inspired by the survey used by Brothers 
et al, I sought to reassess whether BioVU awareness has improved or remained 
stagnant and, if patients were familiar with BioVU, to identify what they knew 
about the project. Additionally, I wanted to ask patients whether they would be 
interested in having more information about BioVU and if they would be willing to 
access that information on a website should they have questions that could not 
be answered upon their first introduction to Vanderbilt University Medical 
Center’s consent process. 
 These sites were chosen because they were similar to the sites selected 
in the study by Brothers and colleagues. The goal was to target a general sample 
of Vanderbilt’s patient population. The sites chosen were also optimal because 
we were certain that every patient that came through the area had been notified 
of BioVU as a program and had been presented with the option to opt-out. 
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Additionally, these sites are some of few that had the BioVU informational 
brochures available to patients. When surveying, the interviewer (AS) would 
open by asking, “Are you leaving an appointment?” Potential participants were 
only eligible if they affirmed they were a patient leaving from a regularly 
scheduled primary care appointment or if they were having their blood drawn. I, 
then followed by asking, “Would you mind taking a few minutes to answer some 
questions for a research survey?” If the potential participants agreed to answer 
my questions, the interviewer the goals of the survey, the requirement for 
anonymity of records, and that they were free to end the interview at any time. As 
there was only one interviewer at any time, several potential participants could 
not be approached while exiting. It was not possible to record the number of 
people who could not be approached because it is not certain how many of them 
would have met the criteria as a potential participant. The interviewer did record 
the number of eligible persons approached whether they declined or agreed to 
continue with the interview. If patients agreed to participate, the interviewer 
continued with the survey that consisted of yes/no questions as well as some 
open-ended free text responses to be coded.  
 
Results1   
 The data collected reflect the outcomes of 61 patient exit-interview 
surveys that were collected between April and May 2014. Of those who were 
approached, 100 people were eligible to complete the survey. Of those 100 
                                                
1 See Appendices for a complete list of tables and figures  
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people, 61 agreed to answer the questions about BioVU. When asked whether 
the patients had heard of Vanderbilt’s DNA databank, BioVU, 50.8% claimed that 
had heard of BioVU. Of those 50.8%, only 25.8% expressed that they had seen 
some sort of advertisement for the project that they could recall. Across the 
population surveyed, there was an overwhelming amount of support expressed in 
favor of researchers at Vanderbilt using leftover, de-identified samples for BioVU 
research. In fact, no one expressed any feelings against research efforts. Only 
13% of respondents had a neutral opinion when it came to BioVU.  
Regardless of their awareness of  BioVU, participants expressed an 
overwhelming amount of support for the research that is done by researchers 
that utilize BioVU as a resource. Of those who were in support of BioVU, 81% 
reported that they supported the use of BioVU samples because they will be 
used by researchers that are doing research that will lead to benefits for society. 
Eleven percent (11%) of participants expressed their support for BioVU in terms 
of their specific trust in Vanderbilt. The expression of trust for Vanderbilt is 
significant to the analysis of these objective findings and will be elaborated on 
later. As for those who expressed neutrality to BioVU, 12% stated that they felt 
that way because they did not know enough about the research that was being 
done through BioVU; 37% felt they did not know enough about BioVU in general 
to have an opinion; 25% were unsure of the benefits of the project; and 62% had 
other reasons for being neutral, such as them being in favor of research as long 
as their genetic materials were not  used; despite the de-identification of BioVU 
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materials, they still expressed concerns about privacy, and worries about profits 
being collected from de-identified patient samples.  
 Despite low patient awareness of BioVU as a project, when patients were 
prompted to remember whether they had opted out of allowing Vanderbilt to use 
their leftover blood for DNA research, 48% of people said they agreed to allow 
Vanderbilt to use their leftover blood, 11% declined, and 41% were unable to 
recall their response. Additionally, when asked whether they would like to have 
more information made available to them 57% said yes. Ninety-one percent 
(91%) wanted to know how the research is benefiting the community, 85% 
wanted to learn more about the studies using BioVU samples, 65% were 
interested in learning more about the de-identification process, and 65% wanted 
to know who has access to the samples.  
Since it was hypothesized that patients would express interest in learning 
more about BioVU, they were also asked whether they had heard of and would 
visit a BioVU website designed for the sole purpose of learning about BioVU. 
Prior to the creation of the website, finding specific information related to BioVU 
was more difficult, especially for patient populations. Only 5% of people had 
heard of the BioVU website. For those who had not, 63% planned to visit the 
website, 10% said they had no plans to do so, and 26% said they might. 73% 
also thought that it would be of use to them to have a feature on the website 
where they could ask questions about the information listed on the BioVU 
website should they have additional concerns.   
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Discussion   
It was found that slightly more than half of patients interviewed were 
aware of BioVU, but when asked what they knew about BioVU only two-thirds of 
them could provide accurate descriptions of BioVU’s practices. Some 
descriptions were more accurate than others.  Some patients could recite the key 
factors, with the most impressive response being:  
It is Vanderbilt’s collection of DNA samples that are extracted from leftover 
blood. They remove all personal information. They asked me about this 
when I was filling out my paperwork.  
This participant not only realized what BioVU was, but could also recall privacy 
practices and where she was first notified of the program. However, while 
responses such as these are most desired by BioVU stakeholders, they were  
rare. Figure 1 illustrates respondents’ confusion concerning the project is evident. 
Most interestingly, there were several patients that confused BioVU with 
Vanderbilt’s personalized medicine marketing campaign. Since both projects are 
related to DNA, this is not that surprising. There were also others that claimed to 
have heard of BioVU, but then admitted to knowing nothing about it other than 
hearing the term. It is likely that some of these recorded responses were from 
people who did not want to risk looking uninformed about BioVU. Although some 
argue that patients’ confusion over biobanking arises because of the similarity 
between biobanking and the collection of other biospecimens for research, I 
would argue that the confusion was solely related to current BioVU practice since 
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the interview questions related only to BioVU rather than including research 
using other biospecimens.  
The problem of confusion is not unique to BioVU. Almost 40% of articles 
on biobanking in Google scholar contained the word “confusion.” Although this is 
a rough measure, it suggests that confusion is a common concern among 
researchers.2 Of these hits, the confusion being referred to differs from article to 
article, based on what the main focus is in terms of ethical problems of interest, 
be it privacy, informed consent, or normative practices and procedures regarding 
how the biobanks are managed. 
For instance, a study conducted by Halverson & Friedman Ross (2012) 
found that a group of 45 self-identified African Americans were confused about 
biobanking practices on three accounts: (1) reasons for consenting to 
participation in biobanks, (2) how the research is or is not related to clinical care, 
and (3) mistrust and misunderstanding about the meaning of the research 
findings. For Knoppers (2005), confusion in biobanking is based on the language 
used to explain identifiability of samples and how the terms are often inconsistent 
with each other. Knoppers explains:  
While international bodies are more explicit in their guidance on “genetic” 
data, confusion still reigns due to the use of different taxonomies and 
overall, the failure to anticipate the need for rules for population biobanks 
and ongoing longitudinal studies. Moreover, the terminology used to 
describe samples and data is still confusion and there is no clarity (p. 9). 
                                                
2 On July 15, I went to Google Scholar’s homepage to conduct an advanced search for the 
terms “biobanking” and “confusion” to appear anywhere in the article limited between 
the years of 2000 and 2014, a total of 3,100 results were found. A search for “biobanking” 
with the same parameters yielded 7,650 articles.  
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Biobanking practices are still new and in development and lacking a standardized 
language; however Knoppers argues for a move towards standardizing norms in 
biobanking to decrease this confusion.  
 Additionally, Hoeyer’s (2008) review of the biobanking literature focuses 
on confusion based on the original establishment of biobanks as well as the laws 
that surround their practice. He explains that the “biobank problem” has been 
influenced by inconsistent consent requirements, and the development of new 
laws has contributed to considerable confusion regarding biobanks. He also 
notes that while there are increasing calls for harmonization of biobanking 
practices, it remains unclear as to who should lead the effort. E.M. Meslin (2010) 
speaks to this well, explaining how the varying interpretations of how the 
Common Rule and regulations regarding consent requirements amplify confusion 
in the US. However, it is also important to note that revisions that have been 
made to the Declaration of Helsinki and the development of the International 
Conference on Harmonization have “created a certain amount of confusion with 
respect to international standards” as well (Meslin, 2010, p. 209). 
While these are only a few examples, the number of hits in the brief 
history of biobanking literature is nothing short of impressive. It is clear that 
biobanking practices are confusing on multiple accounts, both nationally and 
internationally. In addressing the problem of confusion, it is not my goal to 
address every possible issue that biobanking practices globally could develop, 
since most medical and research practices do elicit some level of confusion 
among lay people, as is their nature since this type of knowledge is embedded in 
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the sciences. I do not expect, nor do I propose that, we do everything necessary 
to avoid any confusion since this is an impossible task. Rather, I look at the 
problem of confusion in specific reference to BioVU.  
From my discussions with BioVU planners at the beginning of this project, 
it became clear that confusion was a major concern. BioVU planners and others 
in the Vanderbilt community that identify as stakeholders expressed concerns 
regarding my involvement in a project that would ask patients about BioVU. 
Before I settled on the measures on which this project is based I had originally 
wanted to ask patients whether they understood that even if they declined to 
allow BioVU to store their de-identified DNA samples, their biological specimen 
could still be used for other research. It was expressed by BioVU planners that 
making this distinction this would potentially confuse patients and cause some 
unnecessary anxiety on the part of the patients.; thus my original proposal was 
revised.  
On my alternative path of investigation, I could identify what it is about 
BioVU’s practice that is confusing to patients. BioVU and its processes are 
complex and difficult to understand: even members of the Vanderbilt community 
who are blasted with BioVU’s successes are not necessarily aware of what it is 
or how it works. Despite this fact, if any of them also receive their care from 
Vanderbilt, it is likely that they are participants. In asking those who knew, or 
claimed to know about BioVU, I followed with the statement: “Tell me what you 
know about BioVU.” In using this phrasing rather than asking what patients knew 
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about BioVU, required patients to formulate a response and define BioVU in their 
terms.   
When asked whether patients supported, opposed, or were neutral about 
Vanderbilt-collected DNA from their leftover blood samples, the support was 
remarkably high. BioVU’s contribution to societal benefit was the biggest 
motivating factor cited by patients regarding their reasoning for supporting 
biospecimens research. Interestingly, trust in Vanderbilt also played a role in 
patients’ support for research. With no prompting by the interviewer, 11.3% of 
patients suggested trust and investment in Vanderbilt as something that made 
them believe in the research being done. In this section of the survey, patients 
could list multiple reasons for their interest or disinterest in supporting research 
using de-identified DNA samples from BioVU. While no one overtly opposed 
research using leftover biospecimens, a small number of patients expressed 
feelings of neutrality concerning research using BioVU as a resource because 
they did not feel like the research either directly affected them or they did not 
have enough information to pass judgment. A few patients suggested that they 
do not necessarily oppose research done through BioVU, but they could not 
admit full support because they did not want their genetic materials to be used. 
Acknowledgement and appreciation for societal benefit was not enough to 
convince them to participate in the project. This response may be of the minority 
opinion, but it is important to note that this patient preference cannot be met by 
Vanderbilt’s current research standards pertaining to the use of blood, tissues, or 
any other specimens collected in the clinical setting that fall outside the scope of 
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BioVU. It is this small population of patients that are identified as patients that 
could potentially be upset by the fact that any and all of their biospecimens can 
be used for research, and thus it is their trust in Vanderbilt’s system that is being 
violated.  
Trust is crucial for the success of any major research project. The creation 
of BioVU, and the idea that Vanderbilt should notify its patient community of the 
program, is founded on the notion of trust and maintaining trust between 
institution and the surrounding community.  AS noted by Widdows and Cordell:  
If participants withdraw the biobank fails and if this happens early in the 
process then the substantial set-up costs will be lost and there will be no 
gain at all—therefore ensuring that participants and the wider public are 
appropriately engaged with biobanks and that trust between these groups 
is maintained is crucial (Widdows & Cordell, 2011, p. 215). 
This threat has influenced the practices and procedures of all of the biobanks 
around the world. Engaging in public and community awareness practices have 
been useful in order to gain trust in from the community at large. Vanderbilt has 
done its best to create the most ethical model of practice for our opt-out system, 
but there is still an opportunity to improve the system that exists. BioVU’s 
practices regarding informing or notifying patients can be improved. Rather than 
coddle the existing trust patients have in Vanderbilt as cited by the survey 
participants, Vanderbilt should strive to continue to build trust and increase its 
transparency of research practices and ongoing patient participation in projects 
patients have agreed to participate in.   
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 O’Neill (2004) acknowledges that trust and accountability play a major role 
in debates regarding ethics and healthcare settings. She argues that it is often 
believed that: 
In a mature society…we should not take matters on trust, but rather 
establish robust system of accountability, so replacing trust with structures 
that secure proper control and reporting (p. 269).  
 
However, O’Neill rejects the notion that trust can be eliminated from the 
institutional setting by way of accountability since trust will always exist at some 
form or level. If not at the level of patients in a medical institution, then it will be at 
the level of those responsible for oversight, regulations, and accountability. It 
does not matter that the number of “layers of control, process, measurement and 
informed consent we add, we have in the end to decide whether to place—or 
refuse—trust” (O’Neill, 2004, p. 271). Therefore, the important issue at hand is 
that Vanderbilt needs: 
…To consider which forms of accountability best support which relations 
of trust. (…) The would-be eliminators of trust are neither accurate nor 
coherent when they suggest that all trust must be blind trust and so should 
be eliminated. The serious question is how we can support well-judged 
trust that enables people to gain enough evidence—never, and 
necessarily never, total evidence—to judge whether to place or refuse 
trust. What would it take for us to have forms of accountability that allow 
people to make intelligent and informed judgments about where to place 
their trust? (O’Neill, 2004, p. 271) 
For BioVU to fully respect the trust that they so heavily claim to value, then they 
must fully recognize their accountability as the persons that Vanderbilt has 
entrusted to allow potential participants, Vanderbilt patients, to make an 
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intelligent and informed decision. To this point, it can only be argued that very 
few patients, based on the evidence that I have collected, are informed in making 
that decision.  
Of nearly half of the patients interviewed who acknowledged having heard 
about BioVU, 41% could not remember whether they agreed to participate. This 
is problematic for BioVU planners because patients cannot recall their status as 
participants in the project. If BioVU planners want to advocate that patients are 
aware, then it should be easier for them to remember whether they agreed. The 
ease in forgetting about participation in the project could be attributed to the 
brevity of information with which BioVU is introduced and limited time in which 
patients are asked to fill out general paperwork for the first time. At the time of 
deciding whether to opt-out of BioVU, patients are presented the box shown in 
Figure 2.  
To this point, BioVU planners have been operating from the standard of 
the reasonable person in addressing informed, opt-out consent. The reasonable 
person standard serves as the foundation of informed consent policies, and 
practice in medicine is sourced from law. According to this standard, it is required 
for information to be disclosed as “determined by reference to a hypothetical 
reasonable person”. In medicine, whatever a reasonable person would want to or 
should know about potential risks of medical procedures should be disclosed. As 
noted by Beauchamp and Childress, this standard is not so well developed that it 
is able to avoid encounters with conceptual, moral, and practical difficulties since 
no one has been able to carefully define exactly what a “reasonable person” 
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looks like. This abstraction makes it increasingly complex for physicians, 
researchers, and project managers to really discern what a reasonable patient 
should be told (Beauchamp & Childress, 2009, 123).  
Often it is the case that, unless otherwise specified by federal or 
institutional policies and regulations, the responsibility of discerning what 
information is necessary for patients or researcher subjects to know falls on 
those who take ownership of the consent practice. This is precisely what has 
happened with BioVU. Since the general consent procedures that apply to 
human subjects research, as explained earlier, do not apply to biobanking 
practices, BioVU and other biobanking planners alike have the freedom to 
determine what their potential recruits get to know prior to their participation.  
In the case of the current consent language, very little is shared prior to 
patients approaching the kiosks on which the document appears. Since the 
launch of kiosk-based paperwork in Vanderbilt clinics, opt-out rates have 
increased. In 2007 opt-out rates were at approximately 5%, but in 2013 after the 
2012 launch of the kiosks the opt-out rates increased to nearly 16% for the adult 
patient population.  It is not clear to BioVU planners and stakeholders why these 
rates have increased so significantly, but a few explanations can be inferred. 
Prior to the kiosks, patients were presented with the same paperwork by a 
person and may not have read through the paperwork with the same attention. 
The most positive assumption is that patients assented to participation in BioVU 
because of their trust in Vanderbilt. However, the kiosks make disclosures more 
visible to patients, thus helping patients pay more attention to what they are 
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actually signing. Since the BioVU document is more visible than it was previously, 
those who are opting out are likely doing so for one of two reasons: (1) they 
understand what BioVU is and do not want to participate or (2) they do not fully 
understand and say “no” because they are unsure of what exactly they are 
agreeing to. If patients are opting out due to the latter, those are the patients that 
require more information to make an informed decision. It could be the case that 
if they were given more information, they may choose to participate, thus 
benefiting BioVU’s goals.  
Weir (2004) asks two questions when discussing the “Reasonable Person 
Standard of Disclosure” in the context of storing human biospecimens for use in 
genomic research:  
(1) What information should be disclosed to prospective participants so 
that they will know a research study involves DNA banking?  
(2) What information should be disclosed to prospective participants about 
a research team’s DNA banking practices so that they will have a 
sufficient understanding of the long-term implications of providing a 
blood or other tissue sample for a study? (p. 239)  
Weir argues that informed consent literature has not focused on concerns about 
appropriate disclosure and consent involving the use of tissue samples derived 
via surgery and various clinical tests that are banked to be used indefinitely for 
research purposes which may or may not have to do with the reasons why the 
tissues or biospecimens were obtained from patients in the first place. The 
argument presented here is that the reasonable person standard is the most 
appropriate standard to apply to consent practices based on common general 
assumptions of minimal competency of information, prescriptively identifying risk 
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and liability, and also reflecting self-determination. In the context of biobanking 
research, the reasonable person standard applies to what concerns or questions 
a reasonable person may or may not have in the context that he or she may be 
agreeing to provide a blood sample to be stored in a biobank. Weir identified 
eight interests and concerns that should be included in the information given to 
reasonable persons “placed in the situation of a prospective research 
participant”:  
(1) Will my tissue sample [my DNA sample] be identified or traceable to 
me when it is being studied in the lab?  
(2) What are the chances that information derived from my stored sample 
will get into the wrong hands? 
(3) It is my tissue sample, right?  
(4) Can I withdraw my personal involvement from this research study at 
any time?  
(5) How long do you plan to keep my banked sample?  
(6) If you find out something clinically important about me from my banked 
sample, will you tell me?  
(7) Will other people have access to my DNA sample and data in the 
future? 
(8) Will you or other scientists use my stored tissue sample for secondary 
research studies with different purposes? (Weir, 2004, p. 244) 
 
The answers to these questions are what would satisfy the reasonable person 
standard in terms of biobanking research, especially since these would also 
serve as the appropriate standard to hold to which investigators should be held if 
they were to be collecting materials directly from participants for specific research 
studies.  
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 Following this standard of consent in biobanking practices would classify 
as the gold standard. However, as expressed previously, this is not by any 
means the standard across the board. BioVU does answer all the questions in 
ways that are available to patients, but which are difficult to locate. BioVU can 
advocate that it makes information available to patients, and the website only 
adds to this availability, but the order of events that occur in communicating that 
information is not necessarily well managed. Based on the data collected, BioVU 
planners have failed in keeping patients aware of both BioVU as a project let 
alone their involvement with it.  
BioVU currently does not meeting the standard for adequately informing 
members of the general patient population of their involvement in BioVU. 
Additionally, based on the results of this survey, there are a significant number of 
people who fall under the category of lay patient populations who express 
interest in having more information when the topic is explicitly brought to their 
attention. It is apparent that BioVU’s interests for potential participants are not 
consistent with actual patient interests. This is not to suggest that the information 
has not been available, but it has not been accessible or easily delivered to 
patients. For instance, a person filling out the general paperwork for the first time 
may have a specific question regarding how the information is de-identified so 
they may assess whether they trust the methods that are being used. While front 
desk staff has been prompted to give them the brochures that cover the most 
common questions, the brochures contain limited information. Additionally, 
patients may not even be aware that they can ask more specific questions. In 
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fact, it would potentially be more beneficial to BioVU to provide more adequate 
information because some patients will say no simply because they do not have 
enough information and are not presented with ample opportunity to express 
their questions or concerns.  
Information at the time of decision-making is limited, and can easily be 
forgotten. However, when presented with the option of having more information 
about BioVU, 57.4% said they would be interested. While this is not everyone, 
this is enough of an interest for it to be worth it, on the part of BioVU planners, to 
make information more accessible to patients. Svalastong, Allgaier, Martinelli & 
Gajovic (2014) have explained that public discussions, engagement, and 
dialogue between science and society are crucial for successful, sustainable 
projects that lead to important scientific advances being developed. Knowledge 
that is shared about complex and potentially controversial topics is constantly 
being developed, and the Internet is a useful resource that allows a lot of 
information to be made readily available to the public. BioVU recognizes this and 
has been motivated to make information that was previously inaccessible to 
patient populations available on the website. Many of the patients interviewed 
were interested in having additional information. As the results show, there are 
enough people interested in knowing more that merit BioVU’s efforts to create an 
easily navigable, intelligible website.  
The creation of this website has definitely been a step in the right direction, 
but there is still more that we can do. In order to be more effective BioVU should 
further embrace the fact that “communication is not a one way street but ideally a 
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dynamic dialogue that produces new insights into the issues” (Svalastog, Allgaier, 
Martinelli & Gajovic, 2014, p. 55). Since BioVU planners have placed value in 
public acceptance of the project they also should recognize that public 
acceptance of scientific knowledge is key to legitimacy in the process of decision-
making. Creating better opportunities for dialogue would be more valuable than 
simply creating a website that places information out there for those who may be 
interested in learning more. However, as Svalastog, Allgaier, Martinelli & Gajovic 
argue,  
The delegation of public communication of innovative scientific knowledge 
to public relations experts adds a further source of distortion of the 
communication process. Although communication aims at dialogue, this is 
frequently not achieved due to the variety of communications involved and 
their different goals (p. 54).   
 
When space is actually created for dialogue, it is here that legitimization of the 
decision-making process can occur. With the current set-up, BioVU’s consent 
process does not allow much of a dialogue. Should patients express any interest 
or concern regarding their participation at the time of decision-making, they are 
not presented with enough information unless they ask someone at the front 
desk, whereupon they will be provided a brochure like the one shown in Figures 
3.1 and 3.2, which provides vary basic information in a question and answer 
format. The need for this brochure could be decreased if BioVU planners give 
more information that a reasonable person would want to know when Figure 2 
appears on the kiosk screen.  
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Chapter IV  
 
 
Conclusion 
 
 Since nearly half of the patients interviewed for this project were unaware 
of BioVU, BioVU should consider taking a new approach in raising patients’ 
awareness of the program. The intention to implement and maintain an ethical 
biobanking procedure should be applauded, but there is room for improvement. 
Confusion, trust, and giving patients the information necessary to make an 
informed decision concerning their agreement to participate in BioVU have been 
themes throughout this analysis, all of which can be easily addressed by giving 
more information to patients at the time of making their decision to participate in 
or opt-out of BioVU. Brochures, advertisements, and website access do only so 
much to inform patients of the project, especially since this information is only 
found if the patient goes looking for it after accepting or declining participation.  
Based on the number of survey respondents patients who were interested 
in having more information about BioVU, it would not be a wasted effort to offer 
more information before they are presented with the consent language at the 
kiosk. Rather than propose a drastic restructuring of BioVU procedures, it is more 
appropriate for BioVU to take these results into account and seriously consider 
revising the consent language as if BioVU were operating from an opt-in model. 
The electronic documents should be treated as such so that patients are truly 
given a convenient opportunity to make an informed decision regarding their 
participation in BioVU.  
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Since the rates of general approval for research using leftover 
biospecimens were so high, it can be expected that the opt-out rates will not 
change much. In fact, providing slightly more information may be beneficial to 
BioVU if the opt-out decrease is due to an increase of patient understanding of 
what BioVU is and what it does. Even if the opposite is true, BioVU and 
Vanderbilt should be able to take pride in the fact that they are able to deliver the 
information necessary for patients to make autonomous, informed decisions.  
The kiosk-based consent language should expand beyond simply notifying 
patients that their leftover blood will be used for DNA research in BioVU.  At the 
very least, it needs to be stated that:  
(1) BioVU is Vanderbilt’s DNA biobank 
(2) Leftover blood samples will be used to extract the patient’s DNA 
(3) A de-identified record of the patient’s medical history will be linked to 
the sample  
(4) The samples will be stored indefinitely to be used for research  
This information is present both in BioVU brochures and on the BioVU website, 
but is not conveniently available without patient prompting, assuming that front 
desk staff are available at the time. While it is true that there will be many 
patients that do not care about whether their materials will be used for research, 
nor are interested in this seemingly excess information, it is most fair to everyone  
if this information is presented for those who will want it.  
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Appendix 
A. Tables  
 
  
 
 
 
Table 2.1 Reasons for Supporting BioVU Research    
Research might benefit me or my family someday 9.4% 
BioVU samples will be used to benefit society 81.1% 
I trust research being done at Vanderbilt  11.3% 
The collection of genetic samples will help scientists 
conduct research on why some people get sick and 
others don’t  
17% 
Other 13.2% 
 
 
 
 
 
 
Table 1. Patient Awareness of BioVU    
 Yes No 
Have heard of BioVU 50.8% 49.2% 
Have seen BioVU advertisements  25.8% 74.2% 
Table 2.2 Reasons for Neutrality Towards BioVU Research   
I do not know enough about the research being done by BioVU  12.5% 
I do not know enough about BioVU in general  37.5% 
I am unsure how this will benefit me or society 25.0% 
Other  62.5% 
Table 2.  Opinions About Using Leftover Blood for 
Research  
 
Support  86.9% 
Oppose  0% 
Neutral  13.1% 
Table 3. Information Patients Desire About BioVU  
 
 
How research is benefiting the community 91.4% 
The studies that are using BioVU samples 85.7% 
How the samples are de-identified 65.7% 
Who has access to the samples  65.7% 
Other 2.9% 
 42 
 
B. Figures   
 
 
 
Figure 1. What Patients Knew About BioVU  
“Vanderbilt uses left-over blood to extract DNA to be used for research.”  
 
“It is a DNA bank at Vanderbilt.”  
 
“They use my blood, but don’t know what for. If Vanderbilt asks for it, they can have it.”  
 
“It is Vanderbilt’s collection of DNA samples that are extracted from left-over blood. They remove all personal information. 
They asked me about this when I was filling out my paperwork.”  
 
“Participants are enrolled on a voluntary basis when blood is drawn, DNA is extracted and put into a database after being 
stripped of identifying information for research purposes.” 
 
“Vanderbilt asks permission to collect DNA for research.”  
 
“Just heard about it, but I don’t know what it is.”  
 
“I have heard of BioVU, but I don’t know much about it.”  
 
“I signed a consent form for [Vanderbilt] to use leftover blood specimens for research.” 
 
“[Vanderbilt] takes leftover blood to save for research.” 
 
“I signed something saying its okay for [Vanderbilt] to use extra blood for something.” 
 
“They take leftover blood samples and do studies with it after removing identifiers.” 
 
“[Vanderbilt] uses it to study DNA.” 
 
“[Vanderbilt] saves blood for testing for research.” 
 
“They use leftover blood to collect DNA and [Vanderbilt] de-identifies it.” 
 
“I signed a form and gave consent for leftover blood to be used for research.” 
 
“Leftover blood is used to help further research.” 
 
“[Vanderbilt] uses excess blood for DNA research.” 
 
“They are trying to collect people's DNA to be used for research. The DNA has been de-identified.” 
 
“It is a DNA bank that I signed a form about.” 
 
“I didn't know it was called BioVU, but I signed a waiver giving the project permission.”  
 
“I know nothing except that I agreed to have samples taken that are submitted to the DNA databank.” 
 
“I know nothing. They asked if they could use my DNA for something.”  
 
“I signed a sheet of paper saying they could use my blood for something so [Vanderbilt] could show me compatible drugs.”  
 
“Mapping process to pair drugs and different therapies to individuals.”  
 
“Vanderbilt is trying to figure out people's DNA so they can help find treatments for specific individuals.” 
 
“I received a letter telling me about some of the research being done at Vanderbilt and I read about it there.” 
 
“Saw the information on the brochure.” 
 
“Not much, just heard of it.” 
 
“I have only heard of it, but don't know what it is.” 
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G.  
 
Figure 2. BioVU Consent Language  
BioVU Form:  
DNA Research:  
Leftover blood from tests, treatment, or surgery may also be used for DNA research through the 
Vanderbilt BioVU Program. If I do not what my leftover blood to go to the Vanderbilt BioVU Program 
for DNA research, I must check the box below. If I have questions or want further information on 
BioVU, I may call 866-436-4710.  
 
 I do NOT want blood left over from tests, treatments, or surgery to be used for th Vanderbilt BioVU 
Program for DNA Research.  
 
Patient/Legal Representative________________________________________Date______________ 
(Relationship to Patient)______________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44 
 
H.  
 
Figure 3.1 BioVU Brochure 2014 (Front and Back Covers)  
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I.  
 
Figure 3.2 BioVU Brochure 2014 (Inside Information) 
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